The accounting treatment and final results for 2007 may change based upon final third party valuations regarding these securities. If uncertainties in the credit market continue, these markets deteriorate further or the company experiences any ratings downgrades on its investments in ARS, the company may incur additional impairments to its investment in ARS. The Company believes that based on its current cash, cash equivalents, short and long term bank deposits and marketable securities balances at December 31, 2007 and its expected operating cash flows, the current lack of liquidity of these securities will not have a material impact on the Company's ability to fund its operations, unless this current lack of liquidity persists after the third quarter of 2009.
Details reconciling non-GAAP amounts with GAAP amounts including specified items are provided in the table attached.
Rosetta Genomics reports the following scientific and corporate highlights:
- Squamous vs. Non Squamous non-small cell lung cancer (NSCLC) - Bevacizumab (Avastin(R)) in combination with carboplatin and paclitaxel, is indicated for first line treatment of patients with unresectable, locally advanced, recurrent or metastatic non-squamous, NSCLC cancer, and the package labeling warns that the incidence of severe or fatal hemoptysis was 31% in patients with squamous histology and 2.3% in patients with NSCLC excluding predominant squamous histology. However, no objective, standardized test for differentiating squamous from non-squamous NSCLC is currently available commercially. A novel test to differentiate squamous vs. non-squamous NSCLC based on a single microRNA biomarker applying the Rosetta Genomics technology is being validated and is expected to be filed with the New York Department of Health during H1 2008.
- Mesothelioma vs. Adenocarcinoma - Differentiating between
|SOURCE Rosetta Genomics Ltd|
Copyright©2008 PR Newswire.
All rights reserved